A Nutanix study reveals GenAI is changing organisations' priorities, with security and privacy being a primary concern.

In the closing of the recent trading day, Nutanix (NTNX) stood at $70.28, denoting a -1.83% change from the preceding trading day.

Nutanix improves financials with robust strategies against VMware, offering cost efficiencies. Strong margins ahead, but high ...

As U.S. markets rise, with the Nasdaq leading gains as investors look past tariff threats, there is a renewed interest in identifying stocks that may be trading below their estimated value. In this ...

EL DORADO HILLS, Calif. - Blaize Holdings, Inc. (NASDAQ: BZAI), a developer of AI-enabled edge-optimized solutions with a current market capitalization of $474 million, has announced its financial ...

This article summarizes the most significant insider buying and selling activities for US stocks reported on Thursday, ...

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Nine ...

Rajiv Ramaswami, the President and CEO of Nutanix, Inc. (NASDAQ:NTNX), has sold 95,852 shares of the company's Class A common ...

Nutanix (NTNX) closed the most recent trading day at $70.85, moving -1.03% from the previous trading session. This move lagged the S&P 500's daily gain of 0.36%. On the other hand, the Dow registered ...

Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced that it will report its financial results for the second quarter of fiscal year 2025, which ended January 31, ...

Nutanix, Inc. (NASDAQ: NTNX ), a leader in hybrid multicloud computing, today announced that it will report its financial results for ...

As GenAI application adoption and implementation move at a blasing pace, the ECI uncovered that while the majority of organisations have already implemented a GenAI strategy, implementation targets ...